{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:38:21Z","timestamp":1774611501879,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03196-3","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:06:05Z","timestamp":1648749965000},"page":"2663-2671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical significance of soluble interleukin-2 receptor measurement in patients with idiopathic retroperitoneal fibrosis"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-3676","authenticated-orcid":false,"given":"H. H. S.","family":"Kharagjitsing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. R.","family":"Hendriksz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Fouraux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-1715","authenticated-orcid":false,"given":"E. F. H.","family":"van Bommel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"6","key":"3196_CR1","first-page":"231","volume":"60","author":"EF van Bommel","year":"2002","unstructured":"van Bommel EF (2002) Retroperitoneal fibrosis. Neth J Med 60(6):231\u2013242","journal-title":"Neth J Med"},{"key":"3196_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181afc420","author":"EFH van Bommel","year":"2009","unstructured":"van Bommel EFH, Jansen I, Hendriksz TR et al (2009) Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0b013e3181afc420","journal-title":"Medicine (Baltimore)"},{"key":"3196_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1991.tb15216.x","author":"DV Parums","year":"1991","unstructured":"Parums DV, Choudhury RP, Shields SA et al (1991) Characterisation of inflammatory cells associated with \u201cidiopathic retroperitoneal fibrosis.\u201d Br J Urol. https:\/\/doi.org\/10.1111\/j.1464-410x.1991.tb15216.x","journal-title":"Br J Urol"},{"key":"3196_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2011.02718.x","author":"EF van Bommel","year":"2011","unstructured":"van Bommel EF, de Mol M, Langerak AW et al (2011) Idiopathic retroperitoneal fibrosis mimicking malignant lymphoma. Pathol Int. https:\/\/doi.org\/10.1111\/j.1440-1827.2011.02718.x","journal-title":"Pathol Int"},{"key":"3196_CR5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-8-619","author":"LA Rubin","year":"1990","unstructured":"Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-113-8-619","journal-title":"Ann Intern Med"},{"issue":"5","key":"3196_CR6","first-page":"220","volume":"78","author":"WA Dik","year":"2020","unstructured":"Dik WA, Heron M (2020) Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases. Neth J Med 78(5):220\u2013231","journal-title":"Neth J Med"},{"key":"3196_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104650","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMra1104650","journal-title":"N Engl J Med"},{"key":"3196_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6103064","author":"F Karim","year":"2018","unstructured":"Karim F, Eurelings LEM, Bansie R et al (2018) Soluble interleukin-2 receptor: a potential marker for monitoring disease activity in IgG4-related disease. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2018\/6103064","journal-title":"Mediators Inflamm"},{"key":"3196_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1416739","author":"T Handa","year":"2018","unstructured":"Handa T, Matsui S, Yoshifuji H et al (2018) Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Mod Rheumatol. https:\/\/doi.org\/10.1080\/14397595.2017.1416739","journal-title":"Mod Rheumatol"},{"issue":"3","key":"3196_CR10","first-page":"157","volume":"36","author":"M Akiyama","year":"2018","unstructured":"Akiyama M, Sasaki T, Kaneko Y et al (2018) Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sj\u00f6gren\u2019s syndrome adults from a defined population. Clin Exp Rheumatol 36(3):157\u2013164","journal-title":"Clin Exp Rheumatol"},{"key":"3196_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2011.07.014","author":"A Sakamoto","year":"2012","unstructured":"Sakamoto A, Nagai R, Saito K et al (2012) Idiopathic retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pericarditis\u2013retrospective analysis of 11 case histories. J Cardiol. https:\/\/doi.org\/10.1016\/j.jjcc.2011.07.014","journal-title":"J Cardiol"},{"issue":"7\u20138","key":"3196_CR12","first-page":"561","volume":"52","author":"A Vlug","year":"1994","unstructured":"Vlug A, Nieuwenhuys EJ, van Eijk RV et al (1994) Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris) 52(7\u20138):561\u2013567","journal-title":"Ann Biol Clin (Paris)"},{"key":"3196_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa083","author":"V Raglianti","year":"2020","unstructured":"Raglianti V, Rossi GM, Vaglio A (2020) Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa083","journal-title":"Nephrol Dial Transplant"},{"key":"3196_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/art.41024","author":"M Nicastro","year":"2019","unstructured":"Nicastro M, Vescovini R, Maritati F et al (2019) Fibrocytes in chronic periaortitis: a novel mechanism linking inflammation and fibrosis. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41024","journal-title":"Arthritis Rheumatol"},{"key":"3196_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/art.38032","author":"A Vaglio","year":"2013","unstructured":"Vaglio A, Catanoso MG, Spaggiari L et al (2013) Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.38032","journal-title":"Arthritis Rheum"},{"key":"3196_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs408","author":"D Mangieri","year":"2012","unstructured":"Mangieri D, Corradi D, Martorana D et al (2012) Eotaxin\/CCL11 in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfs408","journal-title":"Nephrol Dial Transplant"},{"key":"3196_CR17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111143","author":"F Kollert","year":"2012","unstructured":"Kollert F, Binder M, Probst C et al (2012) CCL18\u2014potential biomarker of fibroinflammatory activity in chronic periaortitis. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.111143","journal-title":"J Rheumatol"},{"key":"3196_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/nri3156","journal-title":"Nat Rev Immunol"},{"key":"3196_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108515","author":"J Damoiseaux","year":"2020","unstructured":"Damoiseaux J (2020) The IL-2\u2014IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor. Clin Immunol. https:\/\/doi.org\/10.1016\/j.clim.2020.108515","journal-title":"Clin Immunol"},{"key":"3196_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr779","author":"LG Pelkmans","year":"2012","unstructured":"Pelkmans LG, Aarnoudse AJ, Hendriksz TR et al (2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfr779","journal-title":"Nephrol Dial Transplant"},{"key":"3196_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/art.24461","author":"MN Magrey","year":"2009","unstructured":"Magrey MN, Husni ME, Kushner I et al (2009) Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.24461","journal-title":"Arthritis Rheum"},{"key":"3196_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3542-8","author":"LG Pelkmans","year":"2017","unstructured":"Pelkmans LG, Hendriksz TR, Westenend PJ et al (2017) Elevated serum IgG4 levels in diagnosis and treatment response in patients with idiopathic retroperitoneal fibrosis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-017-3542-8","journal-title":"Clin Rheumatol"},{"key":"3196_CR23","doi-asserted-by":"publisher","DOI":"10.1159\/000168489","author":"L N\u00e4ssberger","year":"1992","unstructured":"N\u00e4ssberger L, Sturfelt G, Thysell H (1992) Serum levels of the soluble interleukin-2 receptor are dependent on the kidney function. Am J Nephrol. https:\/\/doi.org\/10.1159\/000168489","journal-title":"Am J Nephrol"},{"key":"3196_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005315","author":"A Verwoerd","year":"2015","unstructured":"Verwoerd A, Vorselaars ADM, Moorsel V, Coline HM et al (2015) Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency. Eur Respir J. https:\/\/doi.org\/10.1183\/09031936.00005315","journal-title":"Eur Respir J"},{"key":"3196_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.034728","author":"A Kuuliala","year":"2006","unstructured":"Kuuliala A, Nissinen R, Kautiainen H et al (2006) Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2004.034728","journal-title":"Ann Rheum Dis"},{"key":"3196_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv148","author":"FE van der Bilt","year":"2016","unstructured":"van der Bilt FE, Hendriksz TR, van der Meijden WA et al (2016) Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfv148","journal-title":"Clin Kidney J"},{"key":"3196_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60934-3","author":"A Vaglio","year":"2011","unstructured":"Vaglio A, Palmisano A, Alberici F et al (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(11)60934-3","journal-title":"Lancet"},{"key":"3196_CR28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-2-200601170-00007","author":"EF van Bommel","year":"2006","unstructured":"van Bommel EF, Hendriksz TR, Huiskes AW et al (2006) Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-144-2-200601170-00007","journal-title":"Ann Intern Med"},{"key":"3196_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2012.11.010","author":"EF van Bommel","year":"2013","unstructured":"van Bommel EF, Pelkmans LG, van Damme H et al (2013) Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2012.11.010","journal-title":"Eur J Intern Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03196-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03196-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03196-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T13:26:37Z","timestamp":1662729997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03196-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["3196"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03196-3","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study involving human participants was in accordance with the 1964 Helsinki Declaration. The study protocol was approved by the institutional review board of the Albert Schweitzer hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}